Isolated Hypoxic Hepatic Perfusion With Orthograde or Retrograde Flow in Patients With Irresectable Liver Metastases Using Percutaneous Balloon Catheter Techniques: A Phase I and II Study

[1]  A. Eggermont,et al.  Isolated hepatic perfusion: experimental evidence and clinical utility. , 2004, The Surgical clinics of North America.

[2]  Y. Ku,et al.  Reductive Surgery Plus Percutaneous Isolated Hepatic Perfusion for Multiple Advanced Hepatocellular Carcinoma , 2004, Annals of surgery.

[3]  S. Steinberg,et al.  Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  P. Kuppen,et al.  Isolated hepatic perfusion with high‐dose melphalan for the treatment of colorectal metastasis confined to the liver , 2003, The British journal of surgery.

[5]  H. Bismuth,et al.  Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. , 2003, Archives of surgery.

[6]  A. Eggermont,et al.  Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion , 2003, British Journal of Cancer.

[7]  H. Schmoll.  The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. , 2002, Seminars in oncology.

[8]  E. Sigurdson,et al.  Surgical treatment of liver metastases. , 2002, Seminars in oncology.

[9]  B. Nordlinger,et al.  Surgical management of hepatic metastases from colorectal malignancies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Kemeny,et al.  Hepatic-arterial chemotherapy. , 2001, The Lancet. Oncology.

[11]  L. Saltz,et al.  New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. , 2001, The Lancet. Oncology.

[12]  S. Libutti,et al.  Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. , 2001, Surgery.

[13]  S. Libutti,et al.  Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. , 2000, The oncologist.

[14]  S. Libutti,et al.  A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  A. Eggermont,et al.  Tumor Necrosis Factor-&agr; Augments Tumor Effects in Isolated Hepatic Perfusion With Melphalan in a Rat Sarcoma Model , 2000, Journal of immunotherapy.

[16]  R. Tollenaar,et al.  Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver , 2000, British Journal of Cancer.

[17]  S. S. Yoon,et al.  Surgical treatment and other regional treatments for colorectal cancer liver metastases. , 1999, The oncologist.

[18]  N. Kemeny,et al.  Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. , 1999, Journal of hepato-biliary-pancreatic surgery.

[19]  M. Choti,et al.  Management of hepatic metastases. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  D. Fraker,et al.  Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Eggermont,et al.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. , 1998, Annals of surgery.

[22]  I. B. Borel Rinkes,et al.  Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[23]  H. Alexander,et al.  Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. , 1998, The cancer journal from Scientific American.

[24]  Y. Kuroda,et al.  Single catheter technique of hepatic venous isolation and extracorporeal charcoal hemoperfusion for malignant liver tumors. , 1997, American journal of surgery.

[25]  I. B. Borel Rinkes,et al.  Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. , 1997, British Journal of Cancer.

[26]  H. Keizer,et al.  Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. , 1996, Japanese journal of clinical oncology.

[27]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Ravikumar,et al.  Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. , 1992, Journal of vascular and interventional radiology : JVIR.

[29]  P. Kuppen,et al.  Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. , 1991, British Journal of Cancer.

[30]  P. Kuppen,et al.  Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer. , 1991, British Journal of Cancer.

[31]  P. Kuppen,et al.  A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. , 1990, British Journal of Cancer.

[32]  U. Tjaden,et al.  Chromatographic analysis of anticancer drugs. , 1990, Journal of chromatography.

[33]  J. K. Martin,et al.  Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. , 1990, Archives of surgery.

[34]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[35]  J. Hannigan,et al.  A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P D Schneider,et al.  A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. , 1987, Annals of surgery.

[37]  B. Teicher,et al.  Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. , 1981, Cancer research.

[38]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .